Interactions of glucose metabolism and chronic heart failure

Experimental and Clinical Endocrinology and Diabetes

Volumn 117, Issue 3, 2009, Pages 99-106

  Clodi, M ^a   Resl, M ^a   Stelzeneder, D ^a   Pacini, G ^b   Tura, A ^b   Mortl D ^a   Struck, J ^d   Morgenthaler, N G ^d   Bergmann, A ^d   Riedl, M ^a   Anderwald Stadler, M ^c   Luger, A ^a   Pacher, R ^a   Hulsmann M ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b CNR   (Italy)

^c Hietzing Hospital Vienna   (Austria)

^d THERMO FISHER SCIENTIFIC   (Germany)

Author keywords

Cardiovascular incidences; Metabolic features; Obesity

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; DIURETIC AGENT; ENALAPRIL; ENDOTHELIN 1; HEMOGLOBIN A1C; INSULIN; METFORMIN; PLACEBO; PROADRENOMEDULLIN; SPIRONOLACTONE; SULFONYLUREA DERIVATIVE; TELMISARTAN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; DIURETIC ACTIVITY; FEMALE; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; HEART FAILURE; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

BENZIMIDAZOLES; BENZOATES; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; CHRONIC DISEASE; HEART FAILURE; HUMANS; LIPID METABOLISM; MIDDLE AGED; OBESITY; TETRAZOLES;

EID: 62749090974     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-2008-1081211     Document Type: Article

References (60)

1. Bobbio M, Ferrua S, Opasich C, Porcu M, Lucci D, Scherillo M, Tavazzi L, Maggioni AP. Survival and hospitalization in heart failure patients with or without diabetes treated with beta-blockers. J Card Fail 2003; 9 (3): 192-202
2. Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, Malik RA, Maser RE, Sosenko JM, Ziegler D. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005; 28 (4): 956-962
3. Chi Lim S, Morgenthaler NG, Subramaniam T, Wu YS, Goh SK, Sum CF. The relationship between adrenomedullin, metabolic factors and vascular function in individuals with type 2 diabetes mellitus. Diabetes Care 2007
4. Chow LT, Chow SS, Anderson RH, Gosling JA. Autonomic innervation of the human cardiac conduction system: changes from infancy to senility - an immunohistochemical and histochemical analysis. Anat Rec 2001; 264 (2): 169-182
5. Diamantopoulos EJ, Andreadis EA, Tsourous GI, Ifanti GK, Katsanou PM, Georgiopoulos DX, Vassilopoulos CV, Dimitriadis G, Raptis SA. Metabolic syndrome and prediabetes identify overlapping but not identical populations. Exp Clin Endocrinol Diabetes 2006; 114 (7): 377-383
6. Doehner W, Rauchhaus M, Godsland IF, Egerer K, Niebauer J, Sharma R, Cicoira M, Florea VG, Coats AJ, Anker SD. Insulin resistance in moderate chronic heart failure is related to hyperleptinaemia, but not to norepinephrine or TNF-alpha. Int J Cardiol 2002; 83 (1): 73-81
7. Gegenhuber A, Struck J, Dieplinger B, Poelz W, Pacher R, Morgenthaler NG, Bergmann A, Haltmayer M, Mueller T. Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure. J Card Fail 2007; 13 (1): 42-49
8. Gegenhuber A, Struck J, Poelz W, Pacher R, Morgenthaler NG, Bergmann A, Haltmayer M, Mueller T. Midregional pro-A-type natriuretic peptide measurements for diagnosis of acute destabilized heart failure in short-of-breath patients: comparison with B-type natriuretic peptide (BNP) and amino-terminal proBNP. Clin Chem 2006; 52 (5): 827-831
9. Hambrecht R, Fiehn E, Yu J, Niebauer J, Weigl C, Hilbrich L, Adams V, Riede U, Schuler G. Effects of endurance training on mitochondrial ultrastructure and fiber type distribution in skeletal muscle of patients with stable chronic heart failure. J Am Coll Cardiol 1997; 29 (5): 1067-1073
10. Hambrecht R, Niebauer J, Fiehn E, Kalberer B, Offner B, Hauer K, Riede U, Schlierf G, Kubler W, Schuler G. Physical training in patients with stable chronic heart failure: effects on cardiorespiratory fitness and ultrastructural abnormalities of leg muscles. J Am Coll Cardiol 1995; 25 (6): 1239-1249
11. Hayashi M, Shimosawa T, Fujita T. Hyperglycemia increases vascular adrenomedullin expression. Biochem Biophys Res Commun 1999; 258 (2): 453-456
12. Hickey MS, Weidner MD, Gavigan KE, Zheng D, Tyndall GL, Houmard JA. The insulin action-fiber type relationship in humans is muscle group specific. Am J Physiol 1995; 269 (1 Pt 1): E150-E154
13. Honjo S, Nichi Y, Wada Y, Hamamoto Y, Koshiyama H. Possible beneficial effect of telmisartan on glycemic control in diabetic subjects. Diabetes Care 2005; 28 (2): 498
14. Hotamisligil GS. The role of TNFalpha and TNF receptors in obesity and insulin resistance. J Intern Med 1999; 245 (6): 621-625
15. Hulsmann M, Berger R, Sturm B, Bojic A, Woloszczuk W, Bergler-Klein J, Pacher R. Prediction of outcome by neurohumoral activation, the six-minute walk test and the Minnesota Living with Heart Failure Questionnaire in an outpatient cohort with congestive heart failure. Eur Heart J 2002; 23 (11): 886-891
16. Katsuki A, Sumida Y, Gabazza EC, Murashima S, Urakawa H, Morioka K, Kitagawa N, Tanaka T, Araki-Sasaki R, Hori Y, Nakatani K, Yano Y, Adachi Y. Acute hyperinsulinemia is associated with increased circulating levels of adrenomedullin in patients with type 2 diabetes mellitus. Eur J Endocrinol 2002; 147 (1): 71-75
17. Katsuki A, Sumida Y, Urakawa H, Gabazza EC, Maruyama N, Morioka K, Kitagawa N, Hori Y, Nakatani K, Yano Y, Adachi Y. Increased oxidative stress is associated with elevated plasma levels of adrenomedullin in hypertensive patients with type 2 diabetes. Diabetes Care 2003; 26 (5): 1642-1643
18. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000; 85 (7): 2402-2410
19. Khan SQ, Dhillon OS, RJ'Brien O, Struck J, Quinn PA, Morgenthaler NG, Squire IB, Davies JE, Bergmann A, Ng LL. C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation 2007; 115 (16): 2103-2110
20. Kinoshita H, Kato K, Kuroki M, Nakamura S, Kitamura K, Hisanaga S, Fujimoto S, Eto T. Plasma adrenomedullin levels in patients with diabetes. Diabetes Care 2000; 23 (2): 253-254
21. Korosoglou G, Humpert PM. Non-invasive diagnostic imaging techniques as a window into the diabetic heart: a review of experimental and clinical data. Exp Clin Endocrinol Diabetes 2007; 115 (4): 211-220
22. Levine TB, Francis GS, Goldsmith SR, Simon AB, Cohn JN. Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. Am J Cardiol 1982; 49 (7): 1659-1666
23. Lillioja S, Young AA, Culter CL, Ivy JL, Abbott WG, Zawadzki JK, Yki-Jarvinen H, Christin L, Secomb TW, Bogardus C. Skeletal muscle capillary density and fiber type are possible determinants of in vivo insulin resistance in man. J Clin Invest 1987; 80 (2): 415-424
24. Linnemann B, Voigt W, Nobel W, Janka HU. C-reactive protein is a strong independent predictor of death in type 2 diabetes: association with multiple facets of the metabolic syndrome. Exp Clin Endocrinol Diabetes 2006; 114 (3): 127-134
25. Marangou AG, Alford FP, Ward G, Liskaser F, Aitken PM, Weber KM, Boston RC, Best JD. Hormonal effects of norepinephrine on acute glucose disposal in humans: a minimal model analysis. Metabolism 1988; 37 (9): 885-891
26. Mari A, Pacini G, Murphy E, Ludvik B, Nolan JJ. A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care 2001; 24 (3): 539-548
27. Martin S, Schramm W, Schneider B, Neeser K, Weber C, Lodwig V, Heinemann L, Scherbaum WA, Kolb H. Epidemiology of complications and total treatment costs from diagnosis of type 2 diabetes in Germany (ROSSO 4). Exp Clin Endocrinol Diabetes 2007; 115 (8): 495-501
28. Massie B, Conway M, Yonge R, Frostick S, Ledingham J, Sleight P, Radda G, Rajagopalan B. Skeletal muscle metabolism in patients with congestive heart failure: relation to clinical severity and blood flow. Circulation 1987; 76 (5): 1009-1019
29. Michel MC, Bohner H, Koster J, Schafers R, Heemann U. Safety of telmisartan in patients with arterial hypertension: an open-label observational study. Drug Saf 2004; 27 (5): 335-344
30. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. Jama 2001; 286 (10): 1195-1200
31. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem 2005; 51 (10): 1823-1829
32. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 2006; 52 (1): 112-119
33. Morgenthaler NG, Struck J, Thomas B, Bergmann A. Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin Chem 2004; 50 (1): 234-236
34. Pacher R, Stanek B, Hulsmann M, Koller-Strametz J, Berger R, Schuller M, Hartter E, Ogris E, Frey B, Heinz G, Maurer G. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol 1996; 27 (3): 633-641
35. Pacini G, Mari A. Methods for clinical assessment of insulin sensitivity and beta-cell function. Best Pract Res Clin Endocrinol Metab 2003; 17 (3): 305-322
36. Paolisso G, Riu S De, Marrazzo G, Verza M, Varricchio M, D'Onofrio F. Insulin resistance and hyperinsulinemia in patients with chronic congestive heart failure. Metabolism 1991; 40 (9): 972-977
37. Papassotiriou J, Morgenthaler NG, Struck J, Alonso C, Bergmann A. Immunoluminometric assay for measurement of the C-terminal endothelin-1 precursor fragment in human plasma. Clin Chem 2006; 52 (6): 1144-1151
38. Pershadsingh HA. Peroxisome proliferator-activated receptor-gamma: therapeutic target for diseases beyond diabetes: quo vadis? Expert Opin Investig Drugs 2004; 13 (3): 215-228
39. Pollare T, Lithell H, Selinus I, Berne C. Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia 1988; 31 (7): 415-420
40. Sainaghi PP, Castello L, Bergamasco L, Carnevale Schianca GP, Bartoli E. Metabolic characteristics of glucose intolerance: the critical role of obesity. Exp Clin Endocrinol Diabetes 2008; 116 (2): 86-93
41. Schwarz PE, Reimann M, Li J, Bergmann A, Licinio J, Wong ML, Bornstein SR. The Metabolic Syndrome-a global challenge for prevention. Horm Metab Res 2007; 39 (11): 777-780
42. Stoiser B, Mortl D, Hulsmann M, Berger R, Struck J, Morgenthaler NG, Bergmann A, Pacher R. PacheCopeptin r, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. Eur J Clin Invest 2006; 36 (11): 771-778
43. Struck J, Morgenthaler NG, Bergman A. Copeptin n, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patients. Peptides 2005; 26 (12): 2500-2504
44. Sugo S, Minamino N, Shoji H, Kangawa K, Matsuo H. Effects of vasoactive substances and cAMP related compounds on adrenomedullin production in cultured vascular smooth muscle cells. FEBS Lett 1995; 369 (2-3): 311-314
45. Sullivan MJ, Knight JD, Higginbotham MB, Cobb FR. Relation between central and peripheral hemodynamics during exercise in patients with chronic heart failure. Muscle blood flow is reduced with maintenance of arterial perfusion pressure. Circulation 1989; 80 (4): 769-781
46. Suskin N, MacKelvie RS, Burns RJ, Latini R, Pericak D, Probstfield J, Rouleau JL, Sigouin C, Solymoss CB, Tsuyuki R, White M, Yusuf S. Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. Eur Heart J 2000; 21 (16): 1368-1375
47. Swan JW, Anker SD, Walton C, Godsland IF, Clark AL, Leyva F, Stevenson JC, Coats AJ. Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J Am Coll Cardiol 1997; 30 (2): 527-532
48. Swan JW, Walton C, Godsland IF, Clark AL, Coats AJ, Oliver MF. Insulin resistance in chronic heart failure. Eur Heart J 1994; 15 (11): 1528-1532
49. Tanner H, Mohacsi P, Fuller-Bicer GA, Rieben R, Meier B, Hess O, Hullin R. Cytokine activation and disease progression in patients with stable moderate chronic heart failure. J Heart Lung Transplant 2007; 26 (6): 622-629
50. Torre-Amione G. Immune activation in chronic heart failure. Am J Cardiol 2005; 95 (11A): 3C-8C; discussion 38C-40C
51. Tsutamoto T, Horie M. Brain natriuretic peptide. Rinsho Byori 2004; 52 (8): 655-668
52. Tsutamoto T, Wada A, Maeda K, Hisanaga T, Maeda Y, Fukai D, Ohnishi M, Sugimoto Y, Kinoshita M. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997; 96 (2): 509-516
53. Tura A, Kautzky-Willer A, Pacini G. Insulinogenic indices from insulin and C-peptide: comparison of beta-cell function from OGTT and IVGTT. Diabetes Res Clin Pract 2006; 72 (3): 298-301
54. Turk HM, Buyukberber S, Sevinc A, Ak G, Ates M, Sari R, Savli H, Cigli A. Relationship between plasma adrenomedullin levels and metabolic control, risk factors, and diabetic microangiopathy in patients with type 2 diabetes. Diabetes Care 2000; 23 (6): 864-867
55. Usui I, Fujisaka S, Yamazaki K, Takano A, Murakami S, Yamazaki Y, Urakaze M, Hachiya H, Takata M, Senda S, Iwata M, Satoh A, Sasaoka T, Ak ND, Temaru R, Kobayashi M. Telmisartan reduced blood pressure and HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic patients. Diabetes Res Clin Pract 2007
56. Vermes E, Ducharme A, Bourassa MG, Lessard M, White M, Tardif JC. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation 2003; 107 (9): 1291-1296
57. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation 2007; 115 (3): 387-397
58. Vitale C, Mercuro G, Castiglioni C, Cornoldi A, Tulli A, Fini M, Volterrani M, Rosano GM. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol 2005; 4: 6
59. Wilson JR, Martin JL, Schwartz D, Ferraro N. Exercise intolerance in patients with chronic heart failure: role of impaired nutritive flow to skeletal muscle. Circulation 1984; 69 (6): 1079-1087
60. Zabetian AHF, Azizi F. Relationship between metabolic syndrome and its components with coronary heart disease in Iranian men and women. Experimental and Clinical Endocrinology & Diabetes 2008, eFirst